Uncontrolled tumor-related pain or impending spinal cord compression.
Patients whose primary tumors arise in the intra-dural soft tissue (eg. brain and spinal cord) are not eligible
Based on prior radiation records, have had most of the tumor volume (> %) previously radiated at doses >=  gray (Gy) without exceeding spinal cord tolerance (combining previous and future radiation dose to  cc of the spinal cord of =<  Gy)
Tumors involving spinal cord or heart
Epidural tumor <  mm from spinal cord
Tumors that are primarily localized within the brainstem or spinal cord
Patients with symptomatic central nervous system (CNS) metastases or other tumor location (such as spinal cord compression, other compressive mass, uncontrolled painful lesion, bone fracture, etc.) necessitating an urgent therapeutic intervention, palliative care, surgery or radiation therapy
Subject has clinical signs suggestive of high or imminent risks for pathological fracture, spinal cord compression and/or cauda equina syndrome
Spinal surgery carried out with the goal of spinal cord decompression and spinal stabilization within  weeks
Lack of adequate (>=  mm) separation between the spinal cord and the tumor on post-operative CT myelogram or MRI perfusion
Extradural tumor in contact with the spinal cord or tumor located where swelling in response to therapy may impinge upon spinal cord
Evidence of spinal cord compression
Presence of tumor cells in the brain or spinal cord which are symptomatic or require treatment
Metastatic disease impinging on the spinal cord or threatening spinal cord compression; patients that have had previous treatment of disease with impinging on the cord with either surgery or radiotherapy with clinical or radiographic evidence of response or stability are eligible
Metastatic disease impinging on the spinal cord or threatening spinal cord compression
Subjects with known symptomatic or impending spinal cord compression, except if subject has received definitive treatment for this and demonstrates evidence of clinically stable disease
Osseous metastases felt in the opinion of the clinician to be high-risk for impending pathologic fracture or spinal cord compression
Spinal cord compression unless good pain control attained
Radiologic or clinical evidence of spinal cord compression
Patients with primary spinal cord tumors
Evidence of disease in sites or extent that, in the opinion of the investigator, would put the patient at risk from therapy with testosterone (e.g. femoral metastases with concern over fracture risk, severe and extensive spinal metastases with concern over spinal cord compression, extensive liver metastases)
Patients with spinal disease
Patients with radiographic or clinical findings of spinal cord compression or cauda equina syndrome with neurologic deficit thought to be due to malignancy
Spinal cord compression, imminent long bone fracture, or any other condition that, in the opinion of the investigator, is likely to require radiation therapy and/or steroids for pain control during the active phase
Has imminent or established cord compression based on clinical findings and/or MRI
Known spinal cord compression
Patients with symptomatic central nervous system (CNS) metastases or other tumor location (such as spinal cord compression, other compressive mass, uncontrolled painful lesion, bone fracture, etc.) necessitating an urgent therapeutic intervention, palliative care, surgery or radiation therapy
Known symptomatic or impending cord compression
Highly symptomatic patients (e.g., declining ECOG performance status; rapidly worsening symptoms; rapid progression of disease; progression of tumor at critical anatomical sites [e.g., spinal cord compression] requiring urgent alternative medical intervention) are not eligible
Pathologic long-bone fractures, imminent pathologic long-bone fracture (cortical erosion on radiography > %) or spinal cord compression
Imminent spinal cord compression based on clinical findings and/or magnetic resonance imaging (MRI); spinal cord compression will be defined as  degree circumferential obliteration of T cerebrospinal fluid signal around the spinal cord; treatment should be completed for spinal cord compression
Patients with untreated spinal cord compression; patients with spinal cord compression may be enrolled if stable after completing surgery (may enroll  days after surgery) or radiation (may enroll  days after treatment) and must be off corticosteroids for at least  days prior to the start of study treatment
Planned treatment site(s) associated with spinal cord compression or canal compromise requiring decompression
Symptomatic or impending spinal cord compression or cauda equina syndrome.
Patients that require urgent therapy due to tumor mass effects or spinal cord compression
Prognostic Index for Spinal Metastases (PRISM) group -
Has tumor primarily localized to the brainstem or spinal cord
Patients with symptomatic metastatic prostate cancer such as moderate to severe pain, impaired organ function, or spinal cord compression will be excluded from this study unless these issues have been taken care of
No history of tumors involving spinal cord or heart
Patients with symptomatic metastatic prostate cancer such as moderate to severe pain, impaired organ function or spinal cord compression will be excluded from this study unless these issues have been taken care of
Quantification of the degree of epidural spinal cord compression as grade C, , or  by magnetic resonance imaging (MRI), with and without contrast sequences; axial T sequence is encouraged but not required
Motor strength >=  out of  in extremity or extremities affected by the level of the spinal cord compression
Frank cord compression or cord compression from bone components or configuration and acute neurological deficits (defined as motor strength < / in extremity or extremities affected by the level of the spinal cord compression)
PHASE II DOSE EXPANSION IN RECURRENT GBM UNDERGOING RESECTION: Has tumor localized primarily to the posterior fossa, spinal cord, or an unresectable location
PHASE I: Tumor localized primarily to the posterior fossa or spinal cord
Patients that require urgent therapy due to tumor mass effects or spinal cord compression
Has imminent or established spinal cord compression based on clinical findings and/or MRI
Cord compression at  non-contiguous sites in the spine
Imminent or established spinal cord compression based on clinical and/or imaging; in subjects with untreated imminent or established spinal cord compression, treatment with standard of care as clinically indicated should be completed at least  weeks before enrollment
Prior radiation >  Gy to any critical normal organ (e.g., lung, liver, spinal cord, both kidneys) within  year of the treatment date
Imminent spinal cord compression based on clinical findings and/or magnetic resonance imaging (MRI); treatment should be completed for spinal cord compression
Patients must have demonstrated progression of disease on MRI or computed tomography (CT) assessment of the spinal cord/cauda within the previous radiation field\r\n* Progression may consist of an increase in maximal dimension of the tumor by >= %, compromise of the spinal cord/cauda equina and/or exiting spinal nerves (assessed clinically or radiographically), or both
Unable to undergo either a myelogram or MRI of spinal cord/cauda equina and/or exiting spinal nerves
Patients who may not receive therapeutically effective doses via an external beam approach to the lesion of interest as specified by the Dose Limit Guidelines \r\n* Evaluation of doses previously delivered to spinal cord/cauda equina and other critical structures (bowel, esophagus, kidneys, rectum) will be taken into consideration\r\n* If repeat irradiation would exceed any normal tissue constraint the patient will be ineligible \r\n* If the total prior radiation dose to the spinal cord/cauda equina and/or sacrum over all prior treatments exceeds  Gy BED (biologically effective dose), the patient will be ineligible
Tumor within  cm of the spinal cord
Evidence of disease in sites or extent that, in the opinion of the investigator, would put the patient at risk from therapy with testosterone (e.g. femoral metastases with concern over fracture risk, spinal metastases with concern over spinal cord compression, lymph node disease with concern for ureteral obstruction)
Metastatic deposits near a great vessel or spinal cord
Subjects with spinal cord compression
Exposure to any prior chemotherapy or steroid use within  days of study-related drug therapy; (steroid use is allowed if necessary to treat spinal cord compression)
Prior radiotherapy to any anatomic regions that would result in overlap of radiation dose distribution to critical structures (esophagus, heart, spinal cord, brachial plexus)
Patients with primarily infra-tentorial or spinal cord tumor are not eligible
Patient with epidural, spinal nerve, and/or cord compression on MRI may be included
Subjects with radiographic signs of excessive intracranial mass effect with associated rapid neurologic deterioration, and/or spinal cord block
Evidence of spinal cord compression or CNS complication unless controlled by appropriate therapy.
Clinical spinal cord compression syndromes (unless patient has undergone treatment, for example, surgery or radiation therapy, and neurological findings are ? Grade  and patient is off corticosteroids for spinal cord edema or on a stable regimen of <  mg/day prednisone equivalent
Patients with primary tumor location of brainstem or spinal cord
Evidence of disease that, in the opinion of the investigator, would put the patient at risk from testosterone therapy (e.g. femoral metastases with concern over fracture risk, spinal metastases with concern over spinal cord compression, lymph node disease with concern for ureteral obstruction)
Spinal cord compression or impending spinal cord compression
Imminent spinal cord compression based on clinical findings and/or magnetic resonance imaging (MRI); treatment should be completed for spinal cord compression
Patients with symptomatic metastatic prostate cancer experiencing moderate to severe pain, impaired organ function or spinal cord compression will be excluded from this study unless these issues have been addressed
Subjects with radiographic signs of excessive intracranial mass effect with associated rapid neurologic deterioration and/or spinal cord block
Tumors primarily localized in the infratentorial compartment or spinal cord  tumors with limited infratentorial compartment or spinal cord involvement are eligible
Pathologic long-bone fractures, imminent pathologic long-bone fracture (cortical erosion on radiography > %) or spinal cord compression
Patients that require urgent therapy due to tumor mass effects or spinal cord compression
Pathologic long-bone fractures, imminent pathologic long-bone fracture (cortical erosion on radiography > %) or spinal cord compression
The entire tumor volume must be included in a treatment field that limits the total spinal cord dose to  Gy (prior plus planned dose)
Current symptomatic cord compression requiring surgery or radiation therapy
Patients must have symptomatic multiple myeloma without advanced organ damage (such as multiple fractures or advanced bone disease causing immobilization, renal failure, spinal cord compression, or organ compromise due to soft tissue plasmacytoma); if immediate therapy with radiation and high-dose steroids (e.g., for spinal cord compression) or if triple therapy is clearly advisable from the start, the patient is not eligible for this trial
Complicated bone metastases including clinical or radiological evidence of spinal cord compression or impending pathological fracture
First day of dosing with tesevatinib is less than  weeks from the last radiotherapy of the brain or spinal cord/cauda equina
No history of tumors involving spinal cord or heart
No tumors involving spinal cord or heart
Subjects must have experienced no more than two skeletal-related events (SREs) prior to study entry defined as: Need for external beam radiotherapy (EBRT) tor bone, pathological bone fracture (excluding major trauma), spinal cord compression and/or orthopedic surgical procedure. Subjects with no prior SREs are not permitted.
Index tumor causing clinical or radiographic evidence of spinal cord or cauda equina compression/effacement
Anticipated treatment of the index tumor that would require iceball formation within . cm of the spinal cord, brain, other critical nerve structure, large abdominal vessel (possibly achieved with additional maneuvers such as hydrodissection)
Patients may have received prior radiotherapy for symptomatic localized bone lesions or impending spinal cord compression only; radiotherapy must be completed at least  days prior to registration and all toxicities must have resolved to =< grade 
Patients with primary spinal cord tumors are eligible. Patients with multi-focal disease within the cerebrum are eligible.
Subject has experienced acute pathologic fracture or spinal cord compression within  days prior to first dose of study therapy
Presence of tumor cells in the brain or spinal cord that have not been treated
Spinal cord compression or impending spinal cord compression
Imminent or established spinal cord compression based on clinical and/or imaging; in patients with untreated imminent or established spinal cord compression, treatment with standard of care as clinically indicated should be completed at least  weeks before enrollment
Following breast cancer disease conditions are not eligible:\r\n* Single bone lesion\r\n* Two or more visceral metastasis\r\n* Single visceral lesion <  cm without any laboratory changes or clinical symptoms due to the metastatic lesion is permitted\r\n* Presence of brain metastases\r\n* Imminent spinal cord compression based on clinical findings and/or MRI\r\n* Impending fracture, spinal cord compression, and/or potentially unstable compression fracture of vertebral body with possibility of cord compression\r\n* Life expectancy severely limited by concomitant illness (less than  months)\r\n* Concurrent external beam radiation therapy to non-target lesion is permitted
Has tumor localized primarily to the brainstem or spinal cord
Has tumor primarily localized to the brainstem or spinal cord
Current or imminent spinal cord compression based on clinical findings and/or magnetic resonance imaging (MRI); treatment should be completed for spinal cord compression
The generated planning target volume  (PTV) must be >  mm from the spinal cord or brain
The generated PTV is located within  mm of spinal cord or brain
Have current spinal cord compression.
Imminent spinal cord compression based on clinical findings and/or magnetic resonance imaging (MRI). Subjects with history of spinal cord compression should have completely recovered
Symptomatic brain or spinal cord metastases (patients must be stable for >  months post radiotherapy or surgery) for subjects with mesothelioma, NSCLC, uveal melanoma excludes subjects with HCC or glioma).
Have active cancer in the brain or spinal cord
Subject has clinical signs suggestive of high or imminent risks for pathological fracture, spinal cord compression and/or cauda equina syndrome.
Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for  days.
Histologically confirmed, previously untreated CD+ classical HL; (participants receiving limited emergent radiation therapy [RT] or steroid therapy - maximum of  days - because of cardiopulmonary decompensation or spinal cord compression will be eligible for protocol enrollment)
Patient with >=  asymptomatic spinal metastases of the thoracic spine OR >=  asymptomatic spinal metastases of the lumbar spine may be included; patients with spinal metastases to multiple vertebral levels may be included at the discretion of the investigator; however, only one vertebral level will be treated
Tumor to be treated should not directly about the spinal cord, and should have at least mm separation from the spinal cord; for patients with tumors closer than mm, inclusion is permissible at the discretion of the treating radiation oncologist such that dosimetric review demonstrates that the total dose to spinal cord is within tolerable range of <  Gy to % partial volume or max point dose  Gy
Patients with evidence of spinal instability OR neurologic deficit resulting from bony compression of neurologic structures
Any patient with symptoms of pain, compression fracture, neurologic deficit attributable to spinal metastases will not be included
Subjects with symptomatic brain metastases, spinal cord compression, or intractable back pain due to a compressive or destructive mass
Patients with untreated spinal cord metastases or metastases close to vital organs (as determined by the principal investigator) are excluded
Must be no clinical or radiographic evidence of spinal cord compression
Prior spinal cord maximum dose at level of vertebral disease must be =<  Gy
Patients with tumors adjacent to a vertebral body are eligible, unless there is demonstrable bone invasion, as long as all gross disease can be covered to the total radiation dose while respecting spinal cord tolerance
Treating physician assesses tumor to be sufficiently distant from sensitive structures to be able to achieve greater than or equal to  Gray (Gy) (i.e., spinal cord tolerance respected in vertebral body metastisis
Patients must have symptomatic multiple myeloma without advanced organ damage (such as multiple fractures or advanced bone disease causing immobilization, renal failure, spinal cord compression, or organ compromise due to soft tissue plasmacytoma); if immediate therapy with radiation and high-dose steroids (e.g., for cord compression) or with bortezomib-based therapy (e.g., for renal failure) is required, the patient is not eligible for this trial
Spinal cord compression within  months
Spinal cord compression or canal compromise requiring decompression,
Index tumor(s) causing clinical or radiographic evidence of spinal cord or cauda equine compression/effacement
Patients with evidence of other tumor masses in the spinal cord will be eligible unless there is evidence of spinal cord block radiographically or clinically
Anatomical considerations:\r\n* If the patient has >=  sites; only the  most painful sites of disease will be treated; or, in the absence of pain, the  levels at greatest risk of impending collapse, based on extent of involvement, presence of posterior element involvement, or biomechanical risk based on location (mid-thoracic area, thoraco-lumbar junction, lumbosacral junction)\r\n* Spinal cord compression with or without peridural spread\r\n* Neurologic compromise due to spinal cord compression
PART II: Participants must be without evidence of active spinal cord compression
Conditions related to tumor, which require emergency treatment (airway compression, spinal cord compression) since enrollment would delay initiation of such therapy
Imminent spinal cord compression based on clinical findings and/or magnetic resonance imaging (MRI); treatment should be completed for spinal cord compression
Symptomatic or impending spinal cord compression or cauda equine syndrome
Symptomatic or impending spinal cord compression or cauda equina syndrome.
Spinal cord or cauda equine compression/effacement in vertebral metastases with neurological symptoms other than just pain for the lesion that is planned for treatment
Patents with cord compression
Frank spinal cord compression or displacement or epidural compression within  mm of the spinal cord
Presence of spinal cord injury including any form of paraplegia or quadriplegia
Peripheral neuropathy caused by tumor infiltration or compression of spinal nerves or surgical trauma
Congenital spinal defect/paraplegia
Index tumor causing clinical or radiographic evidence of spinal cord or cauda equina compression/effacement
Subjects must have experienced no more than two skeletal-related events (SREs) prior to study entry defined as: need for external beam radiotherapy (EBRT) to bone pain, pathological bone fracture (excluding major trauma), spinal cord compression and/or orthopedic surgical procedure. Subjects with no prior SREs are not permitted.
Any spinal pathology which can prevent safe administration of epidural/ spinal anesthesia
Eminent or established cord compression as assessed by medical record review
Spinal cord compression.
Primary brainstem or spinal cord tumor
Spinal cord compression is excluded unless the patient demonstrates good pain control attained through therapy and there is stabilization or recovery of neurological function for two weeks prior to study entry
History of spinal cord compression
Spinal cord compression.
